AO-252 (TACC3 PPI Inhibitor)
First-in-class TACC3 protein-protein interaction inhibitor for women's cancers
Drug · OtherCompany source
Company profile
About A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
Company description A2A Pharmaceuticals official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at A2A Pharmaceuticals?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Bacterial infections
- Brain metastasis
- Endometrial cancer
- Gastric cancer
- Muscular dystrophy
- Ovarian cancer
- Prostate cancer
- Sarcoma
- Triple negative breast cancer
Who it serves
- Pharma
- Research institutions
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
Phase 1 clinical trial progress announced May 2025 with tumor reductions in women's cancers. FDA IND clearance for TACC3 program in 2021. Biomea Fusion JV formation for MLL-Menin program. Dose expansion planned for summer 2025 to include additional cancer types.
Partnerships
Recorded partners
- Biomea Fusion (50-50 JV for MLL-Menin program)
- IndieBio
- Janssen Research & Development
- Johnson & Johnson Innovation
- SOSV
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
SCULPT™ Platform
AI-powered systematic combinatorial drug design platform
Platform · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Isoxazole-pyrimidine derivatives as TACC3 inhibitors: A novel modality to targeted cancer therapy.Bioorganic chemistry · Mar 1, 2025
Artificial Intelligence for COVID-19 Drug Discovery and Vaccine Development.Frontiers in artificial intelligence · Jan 1, 2020
Clinical validation
Clinical-trial records
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain MetastasesNCT06136884 · Sponsor · RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
22% average tumor reduction
67% of Phase 1 patients (4b BID cohort) over approximately 2 months at 160mg dose
No dose limiting toxicity
Phase 1 trial up to 240mg with benign safety profile
Stable disease and tumor size reductions
Achieved in ovarian and endometrial cancer patients by 2025
Phase 1 Clinical Trial - Women's Cancers
Treatment of ovarian, triple negative breast, and endometrial cancer patients with AO-252
22% average tumor reduction in 67% of patients at 160mg dosing over approximately 2 months with no dose-limiting toxicity
Biomea Fusion Joint Venture
50-50 joint venture formation to advance A2A's MLL-Menin program into clinical development
$56M Series A financing raised for Biomea Fusion in 2021
Johnson & Johnson Innovation and Janssen R&D
AI-powered drug discovery platform validation
Awarded Artificial Intelligence for Drug Discovery Quickfire Challenge
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from A2A Pharmaceuticals
Recent articles published on A2A Pharmaceuticals's official website.
A2A TACC3 Program Clinical Progress in Womens Cancers
Read on A2A PharmaceuticalsA2A Pharmaceuticals Appoints CEO
Read on A2A PharmaceuticalsFDA Clearance of IND Application for TACC3 PPI Inhibitor A2A-252 in Women's Cancer
Read on A2A PharmaceuticalsA2A at Biopharma
Read on A2A PharmaceuticalsA2A Panelist
Read on A2A Pharmaceuticals07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.